Does Aetna (CVS Health) Cover Vardenafil (Levitra/Staxyn)?

How Aetna Classifies Vardenafil on Its Formulary

Generic vardenafil appears on most Aetna commercial formularies at Tier 3, the preferred-brand level. This placement means the drug is covered but carries a higher copay than Tier 1 (generic) or Tier 2 (preferred generic) medications. Brand-name Levitra has been moved to Tier 4 (non-preferred brand) or dropped entirely from many Aetna plan documents since generic vardenafil became available in 2018.

Staxyn, the orally disintegrating tablet formulation, is a separate consideration. Because Staxyn contains a different salt form (vardenafil hydrochloride trihydrate) and has no generic equivalent as of mid-2026, Aetna frequently classifies it as non-formulary. Members who need the ODT form should expect to file a formulary exception request.

Aetna operates multiple formulary tiers depending on the specific plan purchased by the employer. Self-funded employer plans can customize drug lists, so a Tier 3 placement on the standard commercial formulary does not guarantee identical coverage on every Aetna card. The most reliable step is to search the Aetna online formulary lookup tool with your specific member ID before filling a prescription.

PDE5 inhibitors as a class have faced variable insurance treatment since the mid-2000s. A 2012 analysis published in the Journal of Sexual Medicine found that only 44% of U.S. commercial plans covered any PDE5 inhibitor without restriction [1]. Aetna's current policy is more permissive than that benchmark, but access still requires documentation.

Prior Authorization Requirements for Vardenafil on Aetna

Aetna assigns a moderate-to-high prior authorization (PA) burden to vardenafil. Your prescriber must submit clinical documentation confirming a diagnosis of erectile dysfunction, along with evidence that the patient has tried and failed (or cannot tolerate) sildenafil.

The standard PA criteria include: a confirmed ED diagnosis (ICD-10 code N52.x), documentation of the underlying cause or contributing condition (diabetes, post-prostatectomy status, hypogonadism), a record of sildenafil trial and the clinical reason it was insufficient, and confirmation that the patient has no contraindicated medications such as nitrates or alpha-blockers at interacting doses.

Turnaround time for a standard PA request is typically 5 to 10 business days on Aetna commercial plans. Urgent requests, defined by Aetna as situations where delay could seriously jeopardize the member's health, receive a decision within 72 hours. ED prescriptions rarely qualify for urgent review, so plan for the longer window.

The American Urological Association (AUA) guidelines on erectile dysfunction recommend PDE5 inhibitors as first-line pharmacotherapy, noting that patient preference and side-effect profile should guide the specific agent chosen [2]. Citing this guideline in the PA letter can strengthen the clinical rationale. Porst et al. demonstrated in a randomized controlled trial (N=580) that vardenafil 20 mg improved erectile function domain scores by 7.7 points over placebo on the IIEF scale (P<0.001), establishing the drug's efficacy in the key registration study [3].

Step Therapy: Why Aetna Requires Sildenafil First

Step therapy is a cost-management protocol where the insurer requires trial of a less expensive medication before approving a costlier alternative. On Aetna plans, sildenafil (generic Viagra) is the designated first-step PDE5 inhibitor because its average wholesale price is 60% to 70% lower than generic vardenafil.

To satisfy step therapy, the prescriber must document that the patient took sildenafil at therapeutic doses (25 mg, 50 mg, or 100 mg) for a reasonable trial period. Aetna does not publish a fixed number of doses that constitutes a "fair trial," but internal guidelines and industry norms suggest at least 4 to 6 attempts at the maximum tolerated dose on separate occasions [4].

Acceptable reasons to bypass the sildenafil step include: documented adverse reactions (headache, flushing, visual disturbances severe enough to discontinue), drug interactions that make sildenafil unsafe (specific CYP3A4 concerns), clinical failure at maximum dose across multiple attempts, or a medical condition that favors vardenafil's pharmacokinetic profile. For instance, vardenafil has a slightly shorter median T-max (0.7 hours vs. 1.0 hour for sildenafil), which some clinicians prefer for patients who report inconsistent sildenafil onset [5].

Patients with diabetes-related ED may have a distinct clinical reason to request vardenafil specifically. A meta-analysis by Jia et al. pooling 14 RCTs found that vardenafil produced a statistically significant improvement in IIEF scores among diabetic men (weighted mean difference 6.3, 95% CI 4.9 to 7.7), with a tolerability profile comparable to sildenafil in this subgroup [6]. Referencing this evidence in a step-therapy exception letter provides measurable support for the prescriber's request.

What Vardenafil Costs on Aetna Plans

Out-of-pocket costs depend on plan design. Here is what members typically see in 2026 across common Aetna commercial tiers.

For generic vardenafil at Tier 3, copays range from $30 to $75 for a 30-day supply (typically 6 to 8 tablets). Plans with coinsurance instead of flat copays charge 25% to 40% of the negotiated price, which can land between $15 and $50 depending on the pharmacy's contracted rate. Mail-order pharmacy options through CVS Caremark (Aetna's integrated PBM) sometimes reduce per-unit costs by 10% to 20% for 90-day fills.

Brand Levitra, when covered at Tier 4, carries copays of $100 to $150 or coinsurance of 40% to 50%. At a list price near $350 per month, the coinsurance route can exceed $150 out of pocket. Staxyn, if approved via formulary exception, often lands at the specialty or non-preferred tier with costs above $200 per month.

Cash-pay alternatives exist outside insurance entirely. GoodRx and similar discount platforms list generic vardenafil 20 mg (6 tablets) at $25 to $90 depending on the pharmacy. For some patients, paying cash for generic vardenafil costs less than the Tier 3 copay, a comparison worth checking at the pharmacy counter before running insurance.

The FDA-approved prescribing information for vardenafil lists three dose strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg for the standard tablet, with the 10 mg dose recommended as the typical starting point [7]. Aetna's quantity limits usually apply to the approved dosing schedule of one tablet per 24-hour period.

How to Appeal an Aetna Denial for Vardenafil

A denied prior authorization is not the final answer. Aetna provides a structured two-level appeal process that gives members and prescribers multiple opportunities to reverse a coverage decision.

First-level internal appeal. The member or prescriber submits a written appeal within 180 days of the denial. Include the original PA denial letter, a letter of medical necessity from the prescribing urologist or primary care physician, supporting clinical evidence (trial data, guideline excerpts), and any patient-specific documentation such as lab results showing testosterone levels, HbA1c, or post-surgical status. Aetna must issue a decision within 30 calendar days for standard appeals or 72 hours for expedited appeals.

External review. If the internal appeal is denied, members in most states can request an independent external review through a state-certified external review organization (ERO). The ERO assigns a physician reviewer who is not affiliated with Aetna. Federal law under the ACA requires insurers to comply with the ERO's decision, making this step binding [8].

Success rates improve with specificity. A 2019 study in Health Affairs found that appeals with attached peer-reviewed evidence and explicit guideline citations were approved 54% of the time, compared to 31% for appeals without clinical references [9]. Attach the Porst et al. key trial data [3], the AUA ED guideline [2], and any documentation of sildenafil failure.

Aetna also allows peer-to-peer review, where the prescribing physician speaks directly with an Aetna medical director. Many clinicians report that peer-to-peer calls resolve borderline cases faster than written appeals. Request this option through the PA department phone number on the back of the member's ID card.

Quantity Limits and Refill Restrictions

Most Aetna plans cap PDE5 inhibitor dispensing at 6 to 12 tablets per 30-day period. This limit applies across the PDE5 class, meaning a member who fills both sildenafil and vardenafil in the same month may hit a combined quantity ceiling.

Refill timing follows standard Aetna pharmacy rules: a new fill is available when 75% of the previous supply's days have elapsed. For a 30-day prescription of 6 tablets, the earliest refill date is day 23. CVS Caremark's automated system enforces this window at point of sale.

Dose-splitting strategies (prescribing 20 mg tablets and splitting to 10 mg) are sometimes used to stretch supply, but Aetna's PA criteria may specify the approved dose strength. If the PA authorizes vardenafil 10 mg, filling 20 mg tablets and splitting them could trigger a rejection at the pharmacy. Clarify the approved strength with the PA department before attempting this approach.

Using Manufacturer Savings Cards with Aetna

Bayer, the original manufacturer of brand Levitra, discontinued its U.S. savings card program after the patent expired. No manufacturer copay card currently exists for generic vardenafil from major generic manufacturers (Teva, Par, Macleods).

For patients prescribed brand Staxyn (still under limited distribution), some specialty pharmacy programs offer copay assistance. Eligibility is typically restricted to commercially insured patients; Medicare Part D, Medicaid, and TRICARE beneficiaries are excluded by federal anti-kickback statute regulations.

Patient assistance programs through organizations like NeedyMeds or RxAssist may offer additional support. These programs generally serve uninsured or underinsured patients rather than those with active Aetna coverage but high cost-sharing.

Coverage for Off-Label Uses

Aetna's PA criteria specify erectile dysfunction as the covered indication for vardenafil. Off-label uses, including Raynaud's phenomenon and pulmonary hypertension (where tadalafil and sildenafil have dedicated FDA approvals under the Adcirca and Revatio brands), are not covered under Aetna's vardenafil policy.

Vardenafil has no FDA-approved indication for weight loss, and no published clinical trial supports this use. PDE5 inhibitors do not have a recognized mechanism of action for body-weight reduction. Aetna will deny PA requests citing weight management as the clinical rationale.

For pulmonary arterial hypertension, prescribers should pursue tadalafil (Adcirca) or sildenafil (Revatio), both of which appear on Aetna's specialty formulary with separate PA pathways established under cardiopulmonary coverage policies.

Medicare Part D and Medicaid Considerations

Medicare Part D plans administered by Aetna (including SilverScript) generally exclude PDE5 inhibitors. The Social Security Act Section 1860D-2(e)(2)(A) permits Part D plans to exclude drugs used for erectile dysfunction, and most plans exercise this option [10]. Medicare Advantage plans with supplemental drug benefits occasionally include limited PDE5 coverage, but this varies by plan and region.

Medicaid coverage for vardenafil differs by state. Federal Medicaid law requires coverage of all FDA-approved drugs from manufacturers that participate in the Medicaid Drug Rebate Program, but states can impose prior authorization and preferred drug list restrictions. In practice, many state Medicaid programs limit PDE5 coverage to 4 to 6 tablets per month with mandatory PA [10].

Members transitioning from commercial Aetna to Medicare or Medicaid should anticipate a coverage gap for vardenafil and discuss cash-pay or discount card options with their pharmacist before the switch date. Generic vardenafil 20 mg at cash-pay rates of $25 to $90 for 6 tablets remains an accessible price point for most patients even without insurance coverage.